Urocortin (human) (trifluoroacetate salt)
目录号 : GC45129
A neuropeptide hormone
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Urocortin is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin II , urocortin III , frog sauvagine, and piscine urotensin I. Human urocortin shares 95% sequence homology with rat urocortin . Urocortin binds to type 1 and 2 CRF receptors as well as CRF binding protein (CRF-BP) with Ki values of 0.41, 1.8, 1.5, and 0.22 nM for human CRF1, rat CRF2α, mouse CRF2β, and human CRF-BP, respectively. It induces cAMP production in CHO cells expressing human CRF1, rat CRF2α, and mouse CRF2β receptors (EC50s = 0.22, 0.32, and 0.13 nM, respectively). Urocortin induces secretion of adrenocorticotropic hormone (ACTH) by rat anterior pituitary cells in a concentration-dependent manner, an effect that can be inhibited by human CRF-BP. It inhibits migration and proliferation of human vascular smooth muscle cells (VSMCs) and reduces LDL-induced foam cell formation in vitro. In vivo, urocortin slows development of aortic atherosclerotic lesions in Apoe-/- mice. Urocortin also decreases food intake in food-deprived and non-deprived rats as well as water intake in water-deprived rats in a dose-dependent manner.
| Cas No. | SDF | ||
| 分子式 | C204H337N63O64•XCF3COOH | 分子量 | 4696.2 |
| 溶解度 | Formic Acid: 1 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2129 mL | 1.0647 mL | 2.1294 mL |
| 5 mM | 0.0426 mL | 0.2129 mL | 0.4259 mL |
| 10 mM | 0.0213 mL | 0.1065 mL | 0.2129 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。